Table 1. Demographic and disease-related variables in the monotherapy and the combination therapy group.

	Monotherapy (n=31)	Combination therapy (n=113)
Age - mean±SD	59.1±14.0 years	55.5±9.8 years
Disease duration - mean±SD	20.5±11.2 years	17.7±9.7 years
RF positive - n (%)	20 (60.4%)	86 (76.8%)
ACPA positive - n (%)	25 (80.6%)	93 (85.3%)
Erosive disease - n (%)	15 (48.4%)	50 (44.6%)

Thirty-one patients (21.5%) were under monotherapy with TNFi and etanercept was the most frequent TNFi in both groups (54.8% vs 50.0%; monotherapy and combination therapy groups, respectively). At the start of the first bDMARD, the monotherapy group had a higher disease activity score 28 - 4 variables (DAS 28 4V; 6.083±0.930 vs 5.605±1.043, $p=0.039$) and a higher simple disease activity score (SDAI; 36.12±11.77 vs 28.76±9.98, $p=0.035$); also, in the monotherapy group more patients had already started the bDMARD in monotherapy (22.6% vs 2.7%, $p<0.001$), less patients were under (38.7% vs 73.2%, $p=0.001$) or had already been treated with (77.4% vs 93.8%, $p=0.007$) methotrexate, in comparison with the combination group therapy.

At the last visit of 2019, the monotherapy group had a higher mean years of duration of iTNF treatment (5.5±5.8 vs 3.4±4.5, $p=0.048$), a higher mean patient global assessment - visual analogue scale (PGA-VAS; 49±18 vs 39±25, $p=0.023$), a higher mean prednisolone equivalent dose in mg/day (7.6±6.3 vs 5.6±3.2, $p=0.045$) and a lower proportion of American College of Rheumatology 50 and 70 responses (ACR 50: 12.9% vs 17.0%, $p=0.023$; ACR 70: 3.2% vs 10.7%, $p=0.045$) in comparison with the combination therapy group.

Conclusion: In line with the literature, our real-life results demonstrate some direct (higher PGA-VAS and lower ACR 50 and 70 responses) and indirect (higher current prednisolone equivalent dose) data that suggest that patients with TNFi monotherapy may have a worst disease activity control in comparison with combination therapy.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.994

AB0113

ANTI-CARBAMYLATED PROTEIN ANTIBODIES POSITIVITY AND DISEASE ACTIVITY IN HISPANIC PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS: AN OBSERVATIONAL STUDY

D. Vega-Morales¹, M. A. Garza Elizondo¹, L. A. Trouw², K. I. González Márquez¹, E. Torres-Lopez³, M. Eguia Bernal¹, S. A. Loredó Alanís¹, T. S. Gracia-Arechiga¹, B. R. Vázquez Fuentes¹, D. D. Castañeda Martínez¹, M. M. Castañeda-Martínez¹, C. V. Solís¹, A. Mendiola-Jiménez¹, M. C. Salinas-Carmona³, P. Herrera-Sandate¹, A. Cárdenas¹, G. E. Rodríguez-Sánchez¹, D. Á. Galarza-Delgado¹. ¹Hospital Universitario Dr. José Eleuterio González, Rheumatology Service, Monterrey, Mexico; ²Leiden University Medical Center (LUMC), Department of Immunohematology and Bloodtransfusion, Leiden, Netherlands; ³Hospital Universitario Dr. José Eleuterio González, Immunology Department, Monterrey, Mexico

Background: Clinically relevant anti-carbamylated (anti-CarP) antibodies are detected in up to 45% of rheumatoid arthritis (RA) patients and are associated with severe radiological progression, higher disease activity, and significantly more disability when studied in early phases of arthritis.

Objectives: We aimed to determine the prevalence of anti-CarP antibodies in Mexican Hispanics with established RA and to assess their relationship with disease activity.

Methods: A cohort study was conducted in 278 patients with established RA during an 18-month follow-up. We measured IgG/IgM/IgA rheumatoid factor (RF), IgG anticitrullinated protein antibodies (ACPA) and IgG/IgM/IgA anti-CarP antibodies using enzyme-linked immunosorbent assay (ELISA). For disease activity, we performed the 28-joint disease activity score with erythrocyte sedimentation rate (DAS28-ESR). Repeated measures one-way ANOVA was used to test the association between anti-CarP IgG antibody status and longitudinal DAS28-ESR scores. Patients were evaluated at baseline and at 6, 12, and 18 months during follow-up.

Results: Anti-CarP IgG antibodies were positive in 47.8% of patients and, accounting for all isotypes, in 9.5% of patients with negative RF and ACPA. Triple antibody positivity was present in 42.6% of patients in our sample. Anti-CarP

IgG antibody positivity did not show statistically significant differences in mean DAS28-ESR when compared to anti-CarP IgG antibody negative patients at baseline, 6, 12 or 18 months.

Conclusion: Anti-CarP IgG antibodies are present in almost 50% of RA patients and, accounting for all isotypes, in 9% of RF and ACPA negative patients. Anti-CarP IgG antibody positivity was not associated to a higher disease activity measured by DAS28-ESR in Hispanic patients with established RA.

References: Shi J, Knevel R, Suwannalai P, Van Der Linden MP, Janssen GMC, Van Veelen PA, et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci U S A. 2011;108:17372–17377.

Table 1. Anti-CarP antibody status by isotype in a cohort of 278 patients with established RA.

	Mean (SD)	Antibody positivity, n (%)	95% CI
RF IgA ^a	266.9 (460.5)	155 (58.9)	53.0 to 64.9
RF IgM ^a	406.8 (611.9)	188 (71.5)	66.0 to 77.0
RF IgG ^a	36.1 (249.6)	44 (16.7)	12.2 to 21.3
ACPA IgG ^a	191.01 (411.1)	144 (54.8)	48.7 to 60.8
Anti-CarP IgA ^b	212.9 (464.2)	74 (26.6)	21.4 to 31.8
Anti-CarP IgM ^b	381.6 (762)	89 (32)	26.5 to 37.5
Anti-CarP IgG ^b	227.5 (402.5)	133 (47.8)	41.9 to 53.8

^aData were available for 263 patients. Units are RU/mL. ^bData were available for 278 patients. Units are AU/mL. RF, rheumatoid factor; ACPA, anticitrullinated protein antibodies; Anti-CarP, anti-carbamylated protein antibodies; IgG, immunoglobulin; SD, standard deviation; 95% CI, 95% confidence intervals.

Figure 1. Mean DAS28-ESR scores over an 18-month follow-up by anti-CarP antibody status with error bars corresponding to 95% CI. With the non-sphericity assumed by Greenhouse-Geisser analysis, a non-significant statistical difference was found among groups in the repeated measures one-way ANOVA ($p = 0.829$). DAS28-ESR, 28-joint disease activity score with erythrocyte sedimentation rate; Anti-CarP, anti-carbamylated protein antibodies; Ig, immunoglobulin.

Figure 1.

Disclosure of Interests: David Vega-Morales Grant/research support from: This research was funded as an Investigator Initiated Study by UCB (IIS-2015-104068). The sponsor did not have any role in the design or outcomes of this study., Mario Alberto Garza Elizondo: None declared, Leendert A Trouw: None declared, Karina Itzel González Márquez: None declared, Ernesto Torres-Lopez: None declared, Myriam Eguia Bernal: None declared, SALVADOR AZAHEL LOREDO ALANIS: None declared, Tayde Sarahi Gracia-Arechiga: None declared, Brenda Roxana Vázquez Fuentes: None declared, Diana Daniela Castañeda Martínez: None declared, Martha Mariana Castañeda-Martínez: None declared, Cesar Vidal Solís: None declared, Andres Mendiola-Jimenez: None declared, Mario Cesar Salinas-Carmona: None declared, Pablo Herrera-Sandate: None declared,

Alberto Cárdenas: None declared, Gerardo Eugenio Rodríguez-Sánchez: None declared, Dionicio Ángel Galarza-Delgado: None declared
DOI: 10.1136/annrheumdis-2021-eular.1289

AB0114 INVESTIGATION OF THE EFFECTS OF EXERCISE ON MIRNA EXPRESSIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Z. B. Özcan¹, F. S. Karaahmetoğlu², M. Z. Çıracı³, H. H. Pençe⁴, M. Vural⁵, E. I. Üstün⁵, A. Kural⁶, S. Kuraş⁴, B. Erdoğan⁴. ¹Hamidiye Faculty of Health Sciences, Medical Biochemistry, Istanbul, Turkey; ²Hamidiye Faculty of Health Sciences, Physical Therapy and Rehabilitation, Istanbul, Turkey; ³Sakarya University Education and Research Hospital, Department of Biochemistry, Sakarya, Turkey; ⁴Istanbul Hamidiye Faculty of Health Sciences, Medical Biochemistry, Istanbul, Turkey; ⁵Istanbul SBU Dr. Sadi Konuk Education and Research Hospital, Physical Medicine and Rehabilitation, Istanbul, Turkey; ⁶Istanbul SBU Dr. Sadi Konuk Education and Research Hospital, Department of Biochemistry, Istanbul, Turkey

Background: The goal of treatment for patients with RA is achieve to remission, or at least a state of low disease activity. Exercise is recommended for patients with RA in addition to drug therapy. It has been found to be effective in greatly improving functionality and reducing cardiovascular risk without exacerbating disease activity. Therefore, it is recommended that all RA patients should be encouraged to include aerobic and resistant exercise training as part of their routine treatment (1).

miRNAs(miRNA) are known to protect the pathophysiological process specific to RA. miRNA-146a is one of the miRNAs extensively studied in RA, its expression was found to be higher in the synovial fluid and synovial tissue of RA patients compared to healthy individuals (2).

Many studies have found that miRNA-146a, along with miRNA-16 and miRNA155 may be related to disease pathology. It has also been found that high levels of miRNA-16 expression correlate with active disease and low levels of expression with inactive disease. It has been found that the increased level of miRNA-155 causes a problem in the modulation of arthritis It has been found that the expression level of miRNA-145 is increased in peripheral blood mononuclear cells of RA patients and synovium supporting osteoclastogenesis (3,4,5).

Objectives: It is aimed to investigate the effect of exercise on microRNA expressions in patients with rheumatoid arthritis (RA).

Methods: 30 patients and 30 healthy controls aged 18-60 years who met the 2010 ACR / EULAR RA criteria were included in the study. A program consisting of strengthening and stretching exercises 2 days a week was applied to the study group for 8 weeks. One day a week, 30 minutes of mild moderate walking was requested. Of the cases at the beginning and at the end of the treatment; 5-10 cc peripheral blood samples were taken into one EDTA tube. Then Numeric Rating Scale (NRS) was used for pain, 28-joint Disease Activity Score (DAS28) was used to calculate disease activity, Health Assessment Questionnaire (HAQ) was used to assess general health and Short Form-36 (SF-36) was used to evaluate quality of life. 5-10 cc peripheral blood samples were taken to only 1 EDTA tube of the control group. In the samples taken, gene expressions of miRNA-146a, miRNA-155, miRNA-16, miRNA-145 were determined by real-time PZR method.

Results: There was a significant difference in DAS28, SF-36, NRS, HAQ scales before and after treatment in the RA group of patients (p 0.05). The expression level of MiRNA-146a does not differ significantly before and after treatment (p> 0.05). However, these two groups differ significantly with the control group (p 0.05). No significant difference was observed in the miRNA-155 and miRNA-16 expression levels in the pretreatment, posttreatment, and control groups (p> 0.05).

Conclusion: Exercise therapy has a good effect on pain, disease activity, quality of life and general health in patients with RA. It has been found that exercise can affect vii some of the miRNAs involved in disease pathogenesis. However, more comprehensive studies are needed.

REFERENCES:

- Cooney JK, Law RJ, Matschke V, Lemmey AB, Moore JP, Ahmad Y, et al. Benefits of exercise in rheumatoid arthritis. *Journal of Aging Research*. 2011. p. 14.
- Abou-Zeid A, Saad M, Soliman E. MicroRNA 146a expression in rheumatoid arthritis: Association with tumor necrosis factor- α and disease activity. *Genet Test Mol Biomarkers*. 2011;15(11):807–12.
- Murata K, Yoshitomi H, Tanida S, Ishikawa M, Nishitani K, Ito H, et al. Plasma and synovial fluid microRNAs as potential biomarkers of rheumatoid arthritis and osteoarthritis. *Arthritis Res Ther*. 2010;12(3):86.

- Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EKL. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. *Arthritis Res Ther*. 2008;10(4):101.
- Evangelatos G, Fragoulis GE, Koulouri V, Lambrou GI. Micronas in rheumatoid arthritis: From pathogenesis to clinical impact. *Autoimmun Rev*. 2019;18(11):102391.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1369

AB0115 COMPARISON OF ULTRASOUND FINDINGS BETWEEN TNF INHIBITORS AND NON-TNF INHIBITORS AT FIRST BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS

T. Okano¹, T. Koike^{2,3}, K. Inui⁴, K. Mamoto¹, Y. Yamada¹, K. Mandai⁴, S. Anno¹, H. Nakamura¹ on behalf of Team RA. ¹Osaka City University Graduate School of Medicine, Department of Orthopedic Surgery, Osaka, Japan; ²Osaka City University Graduate School of Medicine, Center for Senile Degenerative Disorders (CSD), Osaka, Japan; ³Shirahama Foundation for Health and Welfare, Search Institute for Bone and Arthritis Disease (SINBAD), Shirahama, Japan; ⁴Osaka Saiseikai Nakatsu Hospital, Department of Orthopedic Surgery, Osaka, Japan

Background: In rheumatoid arthritis (RA), biologics treatment is one of the effective treatment options. Usually, there is no difference in therapeutic effect regardless of which biologics is used, but the effect for joint synovitis is unknown. Recently, ultrasound (US) has played a role of sensitive imaging modality in the diagnosis and follow-up of patients with RA.

Objectives: The aim of this study was to compare the improvement of US findings between TNF inhibitors and non-TNF inhibitors at first biologics in patients with RA.

Methods: Fifty-four RA patients who started the first biologics from September 2016 to December 2018 were included in this longitudinal study (SPEEDY study, UMIN000028260). All the patients were performed clinical examination, blood test and US examination at baseline, 4, 12, 24, 36 and 52 weeks. A US examination was performed at the bilateral first to fifth metacarpophalangeal (MCP) joints, first interphalangeal (IP) and second to fifth proximal interphalangeal (PIP) joints, wrist joints (three part of radial, medial and ulnar) and first to fifth metatarsophalangeal (MTP) joints, by using HI VISION Ascendus (Hitachi Medical Corporation, Japan) with a multifrequency linear transducer (18-6 MHz). The gray scale (GS) and power Doppler (PD) findings were assessed by the semi-quantitative method (0-3). GS score and PD score (both 0-108 points) were defined as the sum of each score. The change of disease activity and US findings were compared between TNF group and non-TNF group.

Results: Among 54 cases, 32 patients were used TNF inhibitor and 22 were non-TNF inhibitor. Age and duration of RA were significantly higher in the non-TNF group, and MTX dose was significantly lower in the non-TNF group. The baseline inflammatory markers tended to be higher in the non-TNF group and the disease activity was also higher in the non-TNF group. However, the US findings showed no significant difference in both GS and PD between two groups at baseline. US improvement ratio was no difference between TNF group and non-TNF group at 4, 12, 24, 36 and 52 weeks in both GS and PD score. Regardless of the type of biologics, patients with long-term disease duration tended to have poor improvement in US synovial findings.

Table 1. Baseline patient and disease characteristics

	TNF (n=32)	non-TNF (n=22)	P value
Female patients, n (%)	21 (65.6)	16 (72.7)	0.767
Age (years)	63.5±15.4	71.0±9.0	0.030
Disease duration (years)	6.5±8.2	13.0±11.7	0.032
CRP (mg/dl)	1.8±2.5	3.0±3.2	0.170
DAS28-ESR	5.0±1.4	5.8±1.2	0.022
GS score	26.1±18.8	31.8±21.1	0.313
PD score	17.6±11.4	23.1±14.6	0.150

Figure 1. GS and PD improvement ratio at 4, 12, 24, 36 and 52 weeks